Fe-SOD cooperates with Nutlin3 to selectively inhibit cancer cells in vitro and in vivo

Biochemical and Biophysical Research Communications

Volumn 431, Issue 2, 2013, Pages 169-175

  Qin, Yong ^a   Dai, Wei ^a   Wang, Yu ^a   Gong, Xing Guo ^a   Lu, Min ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Cancer targeting; Fe SOD; Nutlin3; ROS; Synergistic inhibition

Indexed keywords

IRON SUPEROXIDE DISMUTASE; LIPOSOME; NUTLIN 3; PROTEIN P27; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL ENCAPSULATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; GENE SILENCING; HOMEOSTASIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN INDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DRUG SYNERGISM; FEMALE; HEP G2 CELLS; HUMANS; IMIDAZOLES; LIPOSOMES; MCF-7 CELLS; MELANOMA, EXPERIMENTAL; MICE; NEOPLASMS; PIPERAZINES; REACTIVE OXYGEN SPECIES; SKIN NEOPLASMS; SUPEROXIDE DISMUTASE; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MURINAE;

EID: 84873473127     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.01.001     Document Type: Article

References (21)

1. Lane D.P. Cancer. p53, guardian of the genome. Nature 1992, 358:15-16.
2. Hainaut P., Hollstein M. P53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 2000, 77:81-137.
3. Vu B.T., Vassilev L. Small-molecule inhibitors of the p53-MDM2 interaction. Curr. Top. Microbiol. Immunol. 2011, 348:151-172.
4. de Lange J., Ly L.V., Lodder K., Verlaan-de Vries M., Teunisse A.F., Jager M.J., Jochemsen A.G. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma. Oncogene 2011, 1105-1116.
5. Ji Z., Njauw C.N., Taylor M., Neel V., Flaherty K.T., Tsao H. p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition. J. Invest. Dermatol. 2011, 356-364.
6. Hori T., Kondo T., Kanamori M., Tabuchi Y., Ogawa R., Zhao Q.L., Ahmed K., Yasuda T., Seki S., Suzuki K., Kimura T. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. Cancer Lett. 2010, 287:98-108.
7. Jin L., Tabe Y., Kojima K., Zhou Y., Pittaluga S., Konopleva M., Miida T., Raffeld M. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett. 2010, 299:161-170.
8. Yang H., Higgins B., Kolinsky K., Packman K., Go Z., Iyer R., Kolis S., Zhao S., Lee R., Grippo J.F., Schostack K., Simcox M.E., Heimbrook D., Bollag G., Su F. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 2010, 70:5518-5527.
9. Luo J., Solimini N.L., Elledge S.J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136:823-837.
10. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., Qian D., Lam J.S., Ailles L.E., Wong M., Joshua B., Kaplan M.J., Wapnir I., Dirbas F.M., Somlo G., Garberoglio C., Paz B., Shen J., Lau S.K., Quake S.R., Brown J.M., Weissman I.L., Clarke M.F. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
11. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discovery 2009, 8:579-591.
12. Huang P., Feng L., Oldham E.A., Keating M.J., Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000, 407:390-395.
13. Lu M., Gong X., Lu Y., Guo J., Wang C., Pan Y. Molecular cloning and functional characterization of a cell-permeable superoxide dismutase targeted to lung adenocarcinoma cells. Inhibition cell proliferation through the Akt/p27kip1 pathway. J. Biol. Chem. 2006, 281:13620-13627.
14. Lu M., Bi C.S., Gong X.G., Chen H.M., Sheng X.H., Deng T.L., Xu K.D. Anti-proliferative effects of recombinant iron superoxide dismutase on HepG2 cells via a redox-dependent PI3k/Akt pathway. Appl. Microbiol. Biotechnol. 2007, 76:193-201.
15. Casalini P., Iorio M.V., Berno V., Bergamaschi A., Borresen Dale A.L., Gasparini P., Orlandi R., Casati B., Tagliabue E., Menard S. Relationship between p53 and p27 expression following HER2 signaling. Breast 2007, 16:597-605.
16. Philipp-Staheli J., Kim K.H., Liggitt D., Gurley K.E., Longton G., Kemp C.J. Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development. Oncogene 2004, 23:905-913.
17. Pelicano H., Carney D., Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Update 2004, 7:97-110.
18. Schumacker P.T. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006, 10:175-176.
19. Zhang Y., Zhao W., Zhang H.J., Domann F.E., Oberley L.W. Overexpression of copper zinc superoxide dismutase suppresses human glioma cell growth. Cancer Res. 2002, 62:1205-1212.
20. Valko M., Rhodes C.J., Moncol J., Izakovic M., Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 2006, 160:1-40.
21. Medema R.H., Kops G.J., Bos J.L., Burgering B.M. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000, 404:782-787.